vs
EXACT SCIENCES CORP（EXAS）与Ryman Hospitality Properties, Inc.（RHP）财务数据对比。点击上方公司名可切换其他公司
EXACT SCIENCES CORP的季度营收约是Ryman Hospitality Properties, Inc.的1.2倍（$878.4M vs $737.8M），Ryman Hospitality Properties, Inc.净利率更高（10.1% vs -9.8%，领先19.9%），EXACT SCIENCES CORP同比增速更快（23.1% vs 13.9%），EXACT SCIENCES CORP自由现金流更多（$120.4M vs $58.5M），过去两年Ryman Hospitality Properties, Inc.的营收复合增速更高（18.2% vs 17.4%）
Exact Sciences是总部位于美国威斯康星州麦迪逊的分子诊断企业，专注于早期癌症检测领域。公司核心产品覆盖结直肠癌筛查与预防场景，其中Cologuard是全球首个获批的结直肠癌粪便DNA检测产品，同时还提供其他多种癌症的筛查服务及精准肿瘤检测解决方案。
莱曼酒店地产是一家主营酒店、度假村、娱乐及媒体业务的企业，得名于旗下位于田纳西州纳什维尔的国家历史地标莱曼礼堂。公司历史可追溯至曾为俄克拉荷马出版公司子公司时期，1983年收购WSM公司后奠定现代业务基础，同时将知名演出IP大奥普里等核心资产纳入麾下。
EXAS vs RHP — 直观对比
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $878.4M | $737.8M |
| 净利润 | $-86.0M | $74.5M |
| 毛利率 | 70.1% | 41.4% |
| 营业利润率 | -9.4% | 19.4% |
| 净利率 | -9.8% | 10.1% |
| 营收同比 | 23.1% | 13.9% |
| 净利润同比 | 90.1% | 3.0% |
| 每股收益（稀释后） | $-0.45 | $1.12 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $878.4M | $737.8M | ||
| Q3 25 | $850.7M | $592.5M | ||
| Q2 25 | $811.1M | $659.5M | ||
| Q1 25 | $706.8M | $587.3M | ||
| Q4 24 | $713.4M | $647.6M | ||
| Q3 24 | $708.7M | $550.0M | ||
| Q2 24 | $699.3M | $613.3M | ||
| Q1 24 | $637.5M | $528.3M |
| Q4 25 | $-86.0M | $74.5M | ||
| Q3 25 | $-19.6M | $34.9M | ||
| Q2 25 | $-1.2M | $71.8M | ||
| Q1 25 | $-101.2M | $63.0M | ||
| Q4 24 | $-864.6M | $72.3M | ||
| Q3 24 | $-38.2M | $59.0M | ||
| Q2 24 | $-15.8M | $100.8M | ||
| Q1 24 | $-110.2M | $42.8M |
| Q4 25 | 70.1% | 41.4% | ||
| Q3 25 | 68.6% | 40.9% | ||
| Q2 25 | 69.3% | 49.7% | ||
| Q1 25 | 70.8% | 44.4% | ||
| Q4 24 | 69.0% | 40.4% | ||
| Q3 24 | 69.4% | 43.1% | ||
| Q2 24 | 69.8% | 48.4% | ||
| Q1 24 | 70.0% | 41.5% |
| Q4 25 | -9.4% | 19.4% | ||
| Q3 25 | -3.0% | 15.0% | ||
| Q2 25 | -0.3% | 21.1% | ||
| Q1 25 | -13.6% | 19.8% | ||
| Q4 24 | -122.8% | 18.6% | ||
| Q3 24 | -5.6% | 19.3% | ||
| Q2 24 | -3.8% | 27.4% | ||
| Q1 24 | -16.7% | 18.2% |
| Q4 25 | -9.8% | 10.1% | ||
| Q3 25 | -2.3% | 5.9% | ||
| Q2 25 | -0.1% | 10.9% | ||
| Q1 25 | -14.3% | 10.7% | ||
| Q4 24 | -121.2% | 11.2% | ||
| Q3 24 | -5.4% | 10.7% | ||
| Q2 24 | -2.3% | 16.4% | ||
| Q1 24 | -17.3% | 8.1% |
| Q4 25 | $-0.45 | $1.12 | ||
| Q3 25 | $-0.10 | $0.53 | ||
| Q2 25 | $-0.01 | $1.12 | ||
| Q1 25 | $-0.54 | $1.00 | ||
| Q4 24 | $-4.69 | $1.12 | ||
| Q3 24 | $-0.21 | $0.94 | ||
| Q2 24 | $-0.09 | $1.65 | ||
| Q1 24 | $-0.60 | $0.67 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $964.7M | $471.4M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $2.4B | $750.2M |
| 总资产 | $5.9B | $6.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
| Q4 25 | $964.7M | $471.4M | ||
| Q3 25 | $1.0B | $483.3M | ||
| Q2 25 | $858.4M | $420.6M | ||
| Q1 25 | $786.2M | $413.9M | ||
| Q4 24 | $1.0B | $477.7M | ||
| Q3 24 | $1.0B | $534.9M | ||
| Q2 24 | $946.8M | $498.4M | ||
| Q1 24 | $652.1M | $465.3M |
| Q4 25 | $2.4B | $750.2M | ||
| Q3 25 | $2.5B | $758.5M | ||
| Q2 25 | $2.5B | $800.4M | ||
| Q1 25 | $2.4B | $531.5M | ||
| Q4 24 | $2.4B | $549.0M | ||
| Q3 24 | $3.2B | $551.9M | ||
| Q2 24 | $3.2B | $562.6M | ||
| Q1 24 | $3.1B | $529.9M |
| Q4 25 | $5.9B | $6.2B | ||
| Q3 25 | $5.9B | $6.2B | ||
| Q2 25 | $5.8B | $6.1B | ||
| Q1 25 | $5.7B | $5.2B | ||
| Q4 24 | $5.9B | $5.2B | ||
| Q3 24 | $6.7B | $5.2B | ||
| Q2 24 | $6.7B | $5.1B | ||
| Q1 24 | $6.4B | $5.1B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $151.7M | $164.7M |
| 自由现金流经营现金流 - 资本支出 | $120.4M | $58.5M |
| 自由现金流率自由现金流/营收 | 13.7% | 7.9% |
| 资本支出强度资本支出/营收 | 3.6% | 14.4% |
| 现金转化率经营现金流/净利润 | — | 2.21× |
| 过去12个月自由现金流最近4个季度 | $356.8M | $232.4M |
8季度趋势，按日历期对齐
| Q4 25 | $151.7M | $164.7M | ||
| Q3 25 | $219.9M | $205.2M | ||
| Q2 25 | $89.0M | $122.5M | ||
| Q1 25 | $30.8M | $98.2M | ||
| Q4 24 | $47.1M | $166.6M | ||
| Q3 24 | $138.7M | $218.1M | ||
| Q2 24 | $107.1M | $184.3M | ||
| Q1 24 | $-82.3M | $7.5M |
| Q4 25 | $120.4M | $58.5M | ||
| Q3 25 | $190.0M | $135.4M | ||
| Q2 25 | $46.7M | $53.0M | ||
| Q1 25 | $-365.0K | $-14.5M | ||
| Q4 24 | $10.7M | $76.0M | ||
| Q3 24 | $112.6M | $85.7M | ||
| Q2 24 | $71.2M | $78.8M | ||
| Q1 24 | $-120.0M | $-72.0M |
| Q4 25 | 13.7% | 7.9% | ||
| Q3 25 | 22.3% | 22.9% | ||
| Q2 25 | 5.8% | 8.0% | ||
| Q1 25 | -0.1% | -2.5% | ||
| Q4 24 | 1.5% | 11.7% | ||
| Q3 24 | 15.9% | 15.6% | ||
| Q2 24 | 10.2% | 12.9% | ||
| Q1 24 | -18.8% | -13.6% |
| Q4 25 | 3.6% | 14.4% | ||
| Q3 25 | 3.5% | 11.8% | ||
| Q2 25 | 5.2% | 10.5% | ||
| Q1 25 | 4.4% | 19.2% | ||
| Q4 24 | 5.1% | 14.0% | ||
| Q3 24 | 3.7% | 24.1% | ||
| Q2 24 | 5.1% | 17.2% | ||
| Q1 24 | 5.9% | 15.0% |
| Q4 25 | — | 2.21× | ||
| Q3 25 | — | 5.88× | ||
| Q2 25 | — | 1.71× | ||
| Q1 25 | — | 1.56× | ||
| Q4 24 | — | 2.30× | ||
| Q3 24 | — | 3.70× | ||
| Q2 24 | — | 1.83× | ||
| Q1 24 | — | 0.17× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
EXAS
| Screening | $695.1M | 79% |
| Precision Oncology | $183.2M | 21% |
RHP
| Hotel Other | $157.7M | 21% |
| Gaylord Opryland | $147.4M | 20% |
| Hotel Transient Rooms | $93.6M | 13% |
| Hotel Food And Beverage Outlets | $92.2M | 12% |
| Gaylord Palms | $88.2M | 12% |
| Jw Marriott Hill Country | $53.7M | 7% |
| Entertainment Admissions And Ticketing | $43.1M | 6% |
| Entertainment Food And Beverage | $38.1M | 5% |
| Entertainment Retail And Other | $28.3M | 4% |
| Ac Hotel | $2.4M | 0% |
